Barbara Schilberg

Advisor and Former CEO

Ms. Schilberg has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO from 2002-2021, BioAdvance committed over $50 million to almost 100 seed-stage companies and technologies focusing in areas including Alzheimer’s disease, cancer, diabetes, obesity and infectious diseases. Those companies have leveraged over $3.75 billion in subsequent capital from venture capital, grants, collaborations, M&A activity and product revenues.

Ms. Schilberg is, or has served as a board member or observer for several BioAdvance portfolio companies including Protez, Avid, Immunome, Jenrin Discovery, Merganser, Novira Pharmaceuticals, Ossianix, Mebias Discovery, One Health, Keriton, ENB Therapeutics and Palvella Therapeutics. Ms. Schilberg also serves on various boards or advisory boards, including the Alliance for Women Entrepreneurs (AWE), the Drexel-Coulter Translational Research Partnership, the Roy and Diana Vagelos Life Sciences & Management Program at the University of Pennsylvania, the Penn Medicine Research Council Meeting, the University City Keystone Innovation Zone, and the University City Science Center’s Phase 1 Ventures.

Before joining BioAdvance she served as a senior executive with four emerging life sciences companies and prior to that was a partner at Morgan Lewis.